authors
- Fox, KAA
- Eikelboom, John
- Anand, Sonia
- Bhatt, DL
- Bosch, Jackie
- Connolly, SJ
- Harrington, RA
- Steg, PG
- Yusuf, Salim
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- May 7, 2019
has subject area
- 1102 Cardiorespiratory Medicine and Haematology (FoR)
- 1103 Clinical Sciences (FoR)
- Aspirin (MeSH)
- Atherosclerosis (MeSH)
- Cardiovascular System & Hematology (Science Metrix)
- Chronic Disease (MeSH)
- Clinical Trials as Topic (MeSH)
- Death (MeSH)
- Drug Therapy, Combination (MeSH)
- Factor Xa Inhibitors (MeSH)
- Fibrinolytic Agents (MeSH)
- Hemorrhage (MeSH)
- Humans (MeSH)
- Myocardial Infarction (MeSH)
- Platelet Aggregation Inhibitors (MeSH)
- Rivaroxaban (MeSH)
- Secondary Prevention (MeSH)
- Stroke (MeSH)
- Thrombosis (MeSH)
- Vascular Diseases (MeSH)
published in
- European Heart Journal Journal